Table 3.

HDAC inhibitors ongoing clinical trials

Medication	Condition	Phase	Clinical Trial	Other drugs
Etinostat	Non-Small Cell Lung Cancer	Phase I/II Study	NCT00387465	5-Azacytidine
	HER2-Positive Metastatic Breast Cancer	Phase I Phase II	NCT01434303	Lapatinib Trastuzumab
	Acute Lymphoblastic Leukemia Bilineage Biphenotipic leukemia	Phase I Study	NCT01132573	Clofarabine
	Hodgkin's Lymphoma	Phase 2	NCT00866333
	Metastatic Renal Cell Carcinoma	Phase I/II Study	NCT01038778	Interleukin 2 Aldesleukin
	Breast Cancer	Phase 2	NCT02115594	Fulvestrant
	Non-Small Lung Cancer, Epigenetic Therapy	Phase 2	NCT01928576	Azacitidine CC-486
Vorinostat	Neimann-Pick Disease	Phase 1 Phase 2	NCT02124083
	Non-Small-Cell Lung Carcinoma	Phase 1	NCT02151721	Gefitinib
	Von Hippel-Lindau Disease	Phase 1	NCT02108002
	Cutaneous T-Cell Lymphoma	Phase 3	NCT01728805	Biological: KW-0761
	Gastric Cancer	Phase 1 Phase 2	NCT01045538	capecitabine cisplatin
	Locally Advanced Non-small Cell Lung Cancer	Phase 1	NCT01059552
	Sickle Cell Disease Sickle Cell Anemia	Phase 2	NCT01000155
Panobinostat (LBH589)	Graft-Versus-Host Disease	Phase 1 Phase 2	NCT01111526
	Melanoma Skin Cancer	Phase 1	NCT02032810	Ipilimumab
	Sickle Cell Disease	Phase 1	NCT01245179
	Prostate Cancer Prostatic Neoplasms	Phase 1	NCT00878436	Bicalutamide
	Diffuse Large B Cell Lymphoma	Phase 2	NCT01282476	Rituximab
Romidepsin Istodax	Lymphoma T-Cell Lymphoma Cutaneous Lymphoma	Phase 1	NCT01902225	Doxil
Givinostat	Chronic Myeloproliferative Neoplasms (cMPN)	Phase 2	NCT01761968
(Belinostat) (PDX101)	Small Cell Lung Carcinoma Malignant Epithelial Neoplasms	Phase 1	NCT00926640
	Neoplasms Lymphomas	Phase 1	NCT01273155
Pracinostat	Myelodysplastic Syndrome	Phase 2	NCT01873703	Azacitidine
Valproic Acid	Cancer	Phase 1	NCT01007695
	High Grade Sarcoma	Phase 1	NCT01010958